Statins don't lower risk of pneumonia in elderlyJune 17, 2009British Medical Journal study includes 3,000 Group Health patients SEATTLE- Taking popular cholesterol-lowering statin drugs, such as Lipitor® (atorvastatin), does not lower the risk of pneumonia. That's the new finding from a study of more than 3,000 Group Health patients published online on June 16 in advance of the British Medical Journal's June 20 print issue. "Prior research based on automated claims data had raised some hope-and maybe some hype-for statins as a way to prevent and treat infections including pneumonia," said Sascha Dublin, MD, PhD, a physician at Group Health and assistant investigator at Group Health Center for Health Studies. "But when we used medical records to get more detailed information about patients, our findings didn't support that approach." In fact, Dublin's population-based case-control study found that pneumonia risk was, if anything, slightly higher (26%) in people using a statin than in those not using any; and this extra risk was even higher (61%) for pneumonia severe enough to require being hospitalized. "As a doctor, I'm a fan of statins for what they've been proven to do: lowering cholesterol and risk of heart disease and stroke in people who've had either disease or are at risk for them," said Dublin. Statins are HMG coenzyme A reductase inhibitors, which also include Zocor® (simvastatin) and Mevacor® (lovastatin). This class of medications lessens inflammation, which plays a role in infections. "But now we and some others have found that statins may have gotten some unearned credit for health benefits that they don't actually have, including preventing pneumonia," Dublin said. Suggestions from prior research had led to calls for expensive randomized controlled trials of statins to prevent or treat infection. "But our study indicates that such trials would be an ill-advised use of limited research funds at this time," she added. Why the discrepancy between this new study and earlier ones? "Healthy-user bias is one reason," said Dublin. In other words, compared to people who don't take statins, those who do may be healthier and have healthier habits that lower their risks of unrelated diseases such as pneumonia. And that's just what she found: Study patients who were on statins were less frail or disabled and also more likely to be vaccinated against flu or pneumococcal pneumonia. They were less likely to smoke, to have dementia, or to need help with bathing or walking. Unlike the previous research on statins and pneumonia, Dublin's study made great efforts to control for this bias, including reviewing medical records in detail for every study subject. It confirmed that every pneumonia event was a true case of pneumonia, which prior studies rarely did. And it focused on relatively healthy elderly people. All had intact immune systems and none lived in a nursing home. She studied the same 65- to 94-year-old patients, with their records coded to protect their privacy, as in earlier Group Health research, published in The Lancet in 2008. That work showed the flu vaccine didn't protect the elderly from pneumonia as much as had been thought. "We did an old-fashioned 'chart review,'" said Dublin. "By reading the text in the medical records, you catch crucial details." Group Health Cooperative Center for Health Studies |
|||||||||||||||||||||
| Related Pneumonia Current Events and Pneumonia News Articles Prioritizing low-cost, simple health measures would save 2.5 million child lives a year Almost a third of the children under age five who die each year could be saved if governments rebalance health spending to ensure low-cost, simple interventions such as safe water and hygiene, bed nets and basic maternal and newborn care, leading aid agency World Vision said today. Currently, 8.8 million children a year die before age five, most of preventable causes. Fewer emergency patients seen within recommended time frame One in four emergency department patients in 2006 waited longer to be evaluated by a clinician than recommended at triage, an increase from one in five in 1997. Possible help in fight against muscle-wasting disease A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease, according to researchers at the University of Oregon and the University of Rochester School of Medicine and Dentistry in New York. Henry Ford Hospital study: A MRSA strain linked to high death rates A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford Hospital study. Commentary warns of unexpected consequences of proton pump inhibitor use in reflux disease Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases. Scientists discover influenza's Achilles heel: Antioxidants As the nation copes with a shortage of vaccines for H1N1 influenza, a team of Alabama researchers have raised hopes that they have found an Achilles' heel for all strains of the flu-antioxidants. Lessons from flu seasons past Pregnant women who catch the flu are at serious risk for flu-related complications, including death, and that risk far outweighs the risk of possible side effects from injectable vaccines containing killed virus, according to an extensive review of published research and data from previous flu seasons. Older Patients with Dementia at Increased Risk for Flu Mortality An epidemiological study on pneumonia and influenza (P&I) in adults age 65 and over reports that patients with dementia are diagnosed with flu less frequently, have shorter hospital stays, and have a fifty percent higher rate of death than those without dementia. OMRF scientists discover promising new path for treating traumas A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes. Scientists create NICE solution to pneumonia vaccine testing problems Medical clinics the world over could benefit from new software* created at the National Institute of Standards and Technology (NIST), where a team of scientists has found a way to improve the efficiency of a pneumonia vaccine testing method developed at the University of Alabama at Birmingham (UAB). More Pneumonia Current Events and Pneumonia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||